Abstract
Justification
Data generated after the first wave has revealed that some children with Coronavirus 19 (COVID-19) can become seriously ill. Multi-inflammatory syndrome in children (MIS-C) and long COVID cause significant morbidity in children. Prolonged school closures and quarantine have played havoc with the psychosocial health of children. Many countries in the world have issued emergency use authorisation (EUA) of selected COVID-19 vaccines for use in children. In India, a Subject Expert Committee (SEC) has recommended the use of Covaxin (Bharat Biotech) for children from the ages of 2–18 years. The recommendation has been given to the Drugs Controller General of India (DCGI) for final approval.
Objective
To provide an evidence-based document to guide the pediatricians on the recommendation to administer COVID vaccines to children, as and when they are available for use.
Process
Formulation of key questions was done by the committee, followed by review of literature on epidemiology and burden of COVID-19 in children, review of the studies on COVID vaccines in children, and the IAP stand on COVID-19 vaccination in children. The available data was discussed in the ACVIP focused WhatsApp group followed by an online meeting on 24 October, 2021, wherein the document was discussed in detail and finalized.
Recommendations
The IAP supports the Government of India’s decision to extend the COVID-19 vaccination program to children between 2–18 years of age. Children with high-risk conditions may be immunized on a priority basis. The IAP and its members should be a partner with the Government of India, in the implementation of this program and the surveillance that is necessary following the roll-out.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72/ 314 cases From the Chinese center for disease control and prevention. JAMA. 2020;323: 1239–42.
Ministry of Health and Family, Government of India. Graphical illustration of data from COVID-19 cases in India. National Centre for Disease 2020. Accessed November 19, 2020. Available from: https://ncdc.gov.in/dashboard.php
Delahoy MJ, Ujamaa D, Whitaker M, et al. Hospitalizations associated with COVID-19 among children and adolescents — COVID-NET, 14 States, March 1, 2020-August 14, 2021. Morb mortal Wkly Rep. 2021;70:1255–60.
Holder J. Children drive britain’s longest-running covid surge. The New York Times [Internet]. 2021 Oct 29; Accessed November 19,2021. Available from: https://www.nytimes.com/interactive/2021/10/29/world/europe/uk-britain-covid-surge.html
Age-wise little change between first and second waves, Health Ministry data shows [Internet]. The Indian Express. 2021 [cited 2021 Dec 16]. Available from: https://indianexpress.com/article/india/age-wise-little-change-between-first-and-second-waves-health-ministry-data-shows-7360821/
Laxminarayan R, Wahl B, Dudala SR, et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. Science. 2020;370:691–7.
Tsankov BK, Allaire JM, Irvine MA, et al. Severe COVID-19 Infection and pediatric comorbidities: A systematic review and meta-analysis. Int J Infect Dis. 2021;103:246–56.
Jat KR, Sankar J, Das RR, et al. Clinical profile and risk factors for severe disease in 402 children hospitalized with SARS-CoV-2 from India: Collaborative Indian Pediatric COVID Study Group. J Trop Pediatr. 2021;67:fmab048
Pande N, Save S, Kondekar A, et al. Clinical profile of children with sars-cov-2 infection from a dedicated covid-19 hospital in India. Current Pediatric Research. 2021;697–703.
D Kitano T, Kitano M, Krueger C, et al. The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: A systematic review of fatality and ICU admission in children worldwide. PLoS One. 2021;16: e0246326.
Takia L, Angurana SK, Nallasamy K, et al. Updated management protocol for multisystem inflammatory syndrome in children (MIS-C). J Trop Pediatr. 2021;67:fmab071.
Bautista-Rodriguez C, Sanchez-de-Toledo J, Clark BC, et al. Multisystem inflammatory syndrome in children: An international survey. Pediatrics. 2021;147:e2020024554.
Tiwari A, Rauf A, Kesavan S, et al. A cohort study of COVID-19 related multisystem inflammatory syndrome in children and adolescents from multiple tertiary care centres in south india. Annals of Rheumatic Diseases. 2021;915–6.
Mehra B, Pandey M, Gupta D, et al. COVID-19 associated multisystem inflammatory syndrome in children: A multicentric retrospective cohort study. Indian J Crit Care Med. 2021;1174–80.
Buonsenso D, Espuny Pujol F, Munblit D, et al. Clinical characteristics, activity levels and mental health problems in children with long COVID: A survey of 510 children [Internet]. Preprints.2021.2021030271.
Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6: e005427.
Coronavirus (COVID-19) latest insights — Office for National Statistics [Internet]. Accessed November 19,2021. Available from:https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections#long-covid
Bartley CM, Johns C, Ngo TT, et al. Anti-SARS-CoV-2 and autoantibody profiles in the cerebrospinal fluid of 3 teenaged patients with COVID-19 and subacute neuropsychiatric symptoms. JAMA Neurol. 2021;e213821.
Goldstein E, Lipsitch M, Cevik M. On the effect of age on the transmission of SARS-CoV-2 in households, schools, and the community. J Infect Dis. 2021;223:362–9.
Park YJ, Choe YJ, Park O, et al. Contact tracing during Coronavirus Disease Outbreak, South Korea, 2020. Emerg Infect Dis. 2020;26:2465–8.
Szablewski CM, Chang KT, Brown MM, et al. SARS-CoV-2 transmission and infection among attendees of an overnight camp — Georgia, June 2020. Morb Mortal Wkly Rep. 2020; 69:1023–5.
Riemersma KK, Grogan BE, Kita-Yarbro A, et al. Shedding of infectious SARS-CoV-2 despite vaccination [Internet]. medRxiv. 2021; 2021.07.31.21261387.
Ghosh R, Dubey MJ, Chatterjee S, Dubey S. Impact of COVID-19 on children: Special focus on the psychosocial aspect. Minerva Pediatr. 2020;72:226–35.
Chawla N, Tom A, Sen MS, Sagar R. Psychological impact of COVID-19 on children and adolescents: A systematic review. Indian J Psychol Med. 2021;43:294–9.
Panda PK, Gupta J, Chowdhury SR, et al. Psychological and behavioral impact of lockdown and quarantine measures for COVID-19 pandemic on children, adolescents and caregivers: A systematic review and meta-analysis. J Trop Pediatr. 2021; 67:fmaa122.
Clemmensen C, Petersen MB, Sørensen TIA. Will the COVID-19 pandemic worsen the obesity epidemic? Nat Rev Endocrinol. 2020;16:469–70.
Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunity. 2020;52:737–41.
Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385:2132–39.
Pai M, Chan B, Stall NM, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus vector COVID-19 vaccination [Internet]. Ontario COVID-19 Science Advisory Table; 2021 May [cited 2021 Nov 19]. Available from: https://covid19-sciencetable.ca/sciencebrief/vaccine-induced-immune-thrombotic-thrombocytopenia-vitt-following-adenovirus-vector-covid-19-vaccination
Frenck RW, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New Engl Med. 2021;385:239–50.
Hause AM, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12–17 years — United States, December 14, 2020–July 16, 2021. Morb Mortal Wkly Rep. 2021;70:1053–8.
Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2021; NEJMoa 2116298. Epub ahead of print.
Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021;NEJMoa2109522.
ModernaTX, Inc. A phase 2/3, two-part, open-label, dose-escalation, age de-escalation and randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to less than 12 years of age [Internet]. clinicaltrials.gov; 2021 Nov [cited 2021 Nov 18]. Report No.: NCT04796896. Available from: https://clinicaltrials.gov/ct2/show/NCT04796896
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation. An Open Label Study With an Open Dose Selection Period to Assess the Safety, Tolerability and Immunogenicity of the Drug “Gam-COVID-Vac, a Combined Vector Vaccine for the Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Virus”, With the Participation of Adolescent Volunteers [Internet]. clinical trials.gov; 2021 Sep [cited 2021 Nov 18]. Report No.: NCT04954092. Available from: https://clinicaltrials.gov/ct2/show/NCT04954092
Bharat Biotech International Limited. A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®) in Healthy Volunteers Ages d”18 to e” 2 Years. [Internet]. clinicaltrials.gov; 2021 Jul. Report No.: NCT04918797. Accessed November 19, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04918797
CTRI [Internet]. Accessed November 19, 2020. Available from: http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=51254&EncHid=&userName=ZyCoV-D
Reuters. India gives emergency approval for world’s first COVID-19 DNA vaccine. Reuters [Internet]. 2021 Aug 20. Accessed November 19, 2020. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/india-approves-zydus-cadilas-covid-19-vaccine-emergency-use-2021-08-20/
CTRI [Internet]. Accessed November 19, 2020. Available from: http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=49327&EncHid=&userName=covovax
CTRI [Internet]. Accessed November 19, 2020. Available from: http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=60393&EncHid=&userName=corbevax
Johnson & Johnson applies for Covid-19 vaccine study in Indian adolescents [Internet]. Hindustan Times. Accessed November 19, 2020. Available from: https://www.hindustantimes.com/india-news/johnson-johnson-applies-for-covid-19-vaccine-study-in-indian-adolescents-101629442683103.html
United Nations Development Programme Improving Vaccination Systems — eVIN [Internet]. UNDP Accessed on Nov 19, 2021. Available from: https://www.in.undp.org/content/india/en/home/projects/gavil.html
67% surveyed Indians have developed antibodies against Coronavirus, 40 crore still at risk: Govt [Internet]. India Today. [cited 2021 Dec 16]. Available from: https://www.indiatoday.in/coronavirus-outbreak/story/fourth-serosurvey-result-67-percent-indians-developed-antibodies-against-covid19-1830443-2021-07-20
Cavanaugh AM, Spicer KB, Thoroughman D, et al. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May-June 2021. Morb Mortal Wkly Rep. 2021;70:1081–3.
Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-Like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity — nine states, January-September 2021. Morb Mortal Wkly Rep. 2021;70:1539–44.
Funding
Funding: None
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests: None stated.
Rights and permissions
About this article
Cite this article
Kasi, S.G., Dhir, S.K., Shah, A. et al. Coronavirus Disease 2019 (COVID-19) Vaccination for Children: Position Statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices. Indian Pediatr 59, 51–57 (2022). https://doi.org/10.1007/s13312-022-2421-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-022-2421-9